Valuation: Everest Organics Limited

Capitalization 424.45Cr 4.68Cr 4.03Cr 3.75Cr 3.5Cr 6.51Cr 7Cr 43Cr 17Cr 202.46Cr 18Cr 17Cr 739.28Cr P/E ratio 2024
675x
P/E ratio 2025 -190x
Enterprise value 465.68Cr 5.13Cr 4.42Cr 4.12Cr 3.83Cr 7.14Cr 7.68Cr 47Cr 19Cr 222.13Cr 19Cr 19Cr 811.1Cr EV / Sales 2024
0.75x
EV / Sales 2025 1.79x
Free-Float
21.3%
Yield 2024 *
-
Yield 2025 -
More valuation ratios * Estimated data
Dynamic Chart
1 day-9.09%
1 week-12.64%
Current month-13.58%
1 month-9.43%
3 months+6.61%
6 months+32.45%
Current year-13.58%
More quotes
1 week 432.75
Extreme 432.75
500.35
1 month 423.15
Extreme 423.15
536.4
Current year 432.75
Extreme 432.75
536.4
1 year 210.95
Extreme 210.95
536.4
3 years 95
Extreme 95
536.4
5 years 95
Extreme 95
536.4
10 years 12.5
Extreme 12.5
536.4
More quotes
Manager TitleAgeSince
Chief Executive Officer 48 -
Director of Finance/CFO 59 28/09/2015
Director TitleAgeSince
Director/Board Member 70 13/11/2024
Director/Board Member 47 29/09/2007
Director/Board Member 48 30/07/2014
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-9.09%-12.64%+64.94%+260.64% 4.68Cr
-1.87%-3.53%-5.35%+61.18% 4.41TCr
+1.97%+2.51%+51.16% - 3.33TCr
-2.07%-0.83%+12.63%+122.70% 3.01TCr
-2.58%-4.65%-3.19%+31.89% 1.24TCr
-1.77%-2.99%-12.15%+97.70% 962.73Cr
-0.68%-3.97%+77.21%+44.68% 839.78Cr
+0.91%+3.27%+49.32%+130.21% 780.96Cr
-.--%+0.14% - - 678.76Cr
-0.77%-0.53%+40.01%-21.47% 672.15Cr
Average -1.60%-2.28%+30.51%+90.94% 1.59TCr
Weighted average by Cap. -0.83%-1.20%+19.64%+75.39%
See all sector performances

Financials

2024 2025
Net sales 198.02Cr 2.18Cr 1.88Cr 1.75Cr 1.63Cr 3.04Cr 3.27Cr 20Cr 7.94Cr 94Cr 8.18Cr 8.02Cr 344.91Cr 159.95Cr 1.76Cr 1.52Cr 1.41Cr 1.32Cr 2.45Cr 2.64Cr 16Cr 6.42Cr 76Cr 6.61Cr 6.47Cr 278.6Cr
Net income 13.92L 15.34T 13.23T 12.31T 11.46T 21.34T 22.96T 1L 55.85T 7L 57.53T 56.35T 24.25L -1.29Cr -1L -1L -1L -1L -2L -2L -13.13L -5L -61.55L -5L -5L -2.25Cr
Net Debt 57Cr 62.78L 54.12L 50.38L 46.9L 87.33L 93.96L 5.8Cr 2.29Cr 27Cr 2.35Cr 2.31Cr 99Cr 41Cr 45.45L 39.18L 36.47L 33.96L 63.22L 68.02L 4.2Cr 1.65Cr 20Cr 1.7Cr 1.67Cr 72Cr
More financial data * Estimated data
Logo Everest Organics Limited
Everest Organics Limited is engaged in manufacturing of active pharmaceutical ingredients (API) and their intermediaries. It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole. The Company’s API’s products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5- Thiazolecarboxylate, Ethyl 2-(3-Formyl -4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl -4-Isobutoxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Cyano -4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, and 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride.
Employees
355
More about the company
Date Price Change Volume
16/26/16 437.10 -9.09% 2,983
14/26/14 480.80 -1.30% 731
13/26/13 487.15 -0.10% 286
12/26/12 487.65 -2.54% 597
09/26/09 500.35 +0.23% 1,135

Delayed Quote Bombay S.E., January 16, 2026 at 03:51 pm IST

More quotes
  1. Stock Market
  2. Equities
  3. EVERESTO6 Stock